GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Cooper Companies Inc (MEX:COO) » Definitions » Change In Payables And Accrued Expense

The Cooper (MEX:COO) Change In Payables And Accrued Expense : MXN0 Mil (TTM As of Oct. 2024)


View and export this data going back to 2014. Start your Free Trial

What is The Cooper Change In Payables And Accrued Expense?

The Cooper's Change In Payables And Accrued Expense for the quarter that ended in Oct. 2024 was MXN0 Mil. It means The Cooper's Accounts Payable & Accrued Expense stayed the same from Jul. 2024 to Oct. 2024 .

The Cooper's Change In Payables And Accrued Expense for the fiscal year that ended in Oct. 2024 was MXN-50 Mil. It means The Cooper's Accounts Payable & Accrued Expense declined by MXN50 Mil from Oct. 2023 to Oct. 2024 .


The Cooper Change In Payables And Accrued Expense Historical Data

The historical data trend for The Cooper's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Cooper Change In Payables And Accrued Expense Chart

The Cooper Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.91 1,091.26 1,089.66 1,386.47 -50.08

The Cooper Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

The Cooper Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


The Cooper Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of The Cooper's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


The Cooper Business Description

Address
6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.